Compare Core Scientific Inc (CORZ) vs Crispr Therapeutics AG (CRSP) Price & Performance

Core Scientific (CORZ) trades at $20.87, up 5.62% today, amid strong analyst optimism with 86% buy ratings and a $35.71 consensus price target. The stock shows bearish technical signals but benefits from recent AI infrastructure partnerships, including a major deal with AMD for up to 2.5 gigawatts of data center capacity. Despite negative profitability metrics, revenue growth is projected from $319M in 2025 to $440M in 2026, driven by high-density colocation services.

The outlook is mixed: significant growth potential exists from AI-driven demand and long-term contracts, but high cash burn and negative margins pose risks. Investors should weigh the bullish analyst sentiment against fundamental challenges, including a net income margin of -324.9% and substantial earnings misses in recent quarters.

CRISPR Therapeutics (CRSP) trades at $53.99, down 0.15% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by 151% YoY growth in CASGEVY sales to $76 million. Financials show deep losses with a net income margin of -4,101.26% in 2025, though cash flow improved to a net positive $49.30M. Recent news highlights strong analyst optimism and pipeline advancements.

Outlook remains speculative with high growth potential from gene-editing therapies like CASGEVY, but significant risks persist from ongoing losses and clinical trial outcomes. Wall Street consensus is bullish with a $82.67 price target, implying 53% upside, though investors face volatility from earnings misses and cash burn.